Literature DB >> 33482027

Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells.

Teresa Pollicino1,2, Guido Ferlazzo3,1,4, Claudia De Pasquale3,1, Stefania Campana3,1, Chiara Barberi5, Giacomo Sidoti Migliore5, Daniela Oliveri4, Marika Lanza6, Cristina Musolino6,2, Giovanni Raimondo6,2, Soldano Ferrone7.   

Abstract

BACKGROUND AND AIMS: Natural killer (NK) cells play a crucial role in the clearance of human viruses but their activity is significantly impaired in patients infected with chronic hepatitis B (CHB). Cooperation with dendritic cells (DCs) is pivotal for obtaining optimal NK cell antiviral function; thus, we investigated whether HBV might impact the ability of DCs to sustain NK cell functions. APPROACH AND
RESULTS: Human DCs were poor stimulators of interferon-gamma (IFN-γ) production by NK cells when exposed to HBV, while maintaining the capability to trigger NK cell cytotoxicity. HBV prevented DC maturation but did not affect their expression of human leukocyte antigen class I, thus allowing DCs to evade NK cell lysis. Tolerogenic features of DCs exposed to HBV were further supported by their increased expression of IL-10 and the immunosuppressive enzyme indoleamine 2,3-dioxygenase, which contributed to the impairment of DC-mediated NK cell IFN-γ production and proliferation, respectively. HBV could also inhibit the expression of inducible immunoproteasome (iP) subunits on DCs. In fact, NK cells could induce iP subunit expression on DCs, but they failed in the presence of HBV. Remarkably, circulating blood DC antigen1 (BDCA1)+ DCs isolated from patients with CHB were functionally compromised, hence altering, in turn, NK cell responses.
CONCLUSIONS: The abnormal NK-DC interplay caused by HBV may significantly impair the efficacy of antiviral immune response in patients with CHB.
© 2021 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33482027      PMCID: PMC8295401          DOI: 10.1002/hep.31725

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  45 in total

1.  HLA class I molecule expression is up-regulated during maturation of dendritic cells, protecting them from natural killer cell-mediated lysis.

Authors:  G Ferlazzo; C Semino; G Melioli
Journal:  Immunol Lett       Date:  2001-02-01       Impact factor: 3.685

Review 2.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

3.  Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining.

Authors:  T Ogino; X Wang; S Kato; N Miyokawa; Y Harabuchi; S Ferrone
Journal:  Tissue Antigens       Date:  2003-11

4.  Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses.

Authors:  Scott E Hensley; Damien Zanker; Brian P Dolan; Alexandre David; Heather D Hickman; Alan C Embry; Cara N Skon; Kristie M Grebe; Thomas A Griffin; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2010-03-12       Impact factor: 5.422

5.  Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.

Authors:  Paula Bonorino; Muhammad Ramzan; Xavier Camous; Tania Dufeu-Duchesne; Marie-Ange Thélu; Nathalie Sturm; Aurélie Dariz; Christiane Guillermet; Martine Pernollet; Jean-Pierre Zarski; Patrice N Marche; Vincent Leroy; Evelyne Jouvin-Marche
Journal:  J Hepatol       Date:  2009-06-25       Impact factor: 25.083

6.  Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.

Authors:  Michael D Robek; Mayra L Garcia; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.

Authors:  Barbara Oliviero; Stefania Varchetta; Enrica Paudice; Giuseppe Michelone; Marco Zaramella; Domenico Mavilio; Francesca De Filippi; Savino Bruno; Mario U Mondelli
Journal:  Gastroenterology       Date:  2009-05-24       Impact factor: 22.682

Review 8.  Innate immunity to virus infection.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

9.  Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases.

Authors:  X-L Wei; M-Z Qiu; Y Jin; Y-X Huang; R-Y Wang; W-W Chen; D-S Wang; F Wang; H-Y Luo; D-S Zhang; F-H Wang; Y-H Li; R-H Xu
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

10.  NK cells: a double-edged sword in chronic hepatitis B virus infection.

Authors:  Mala K Maini; Dimitra Peppa
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more
  4 in total

1.  Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment.

Authors:  Weihua Cao; Si Xie; Lu Zhang; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Ruyu Liu; Min Chang; Shuling Wu; Ge Shen; Jianping Dong; Yao Xie; Minghui Li
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 2.  Innate immunity and HBV persistence.

Authors:  Carolina Chiale; Anthony M Marchese; Michael D Robek
Journal:  Curr Opin Virol       Date:  2021-05-13       Impact factor: 7.121

3.  Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B.

Authors:  Minghui Li; Yuanjiao Gao; Liu Yang; Yanjie Lin; Wen Deng; Tingting Jiang; Xiaoyue Bi; Yao Lu; Lu Zhang; Ge Shen; Ruyu Liu; Shuling Wu; Min Chang; Mengjiao Xu; Leiping Hu; Rui Song; Yuyong Jiang; Wei Yi; Yao Xie
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

4.  Letter to the Editor: Entecavir Treatment Restores the Anti-HBV Immune response?

Authors:  Boris J B Beudeker; Harry L A Janssen; Andre Boonstra
Journal:  Hepatology       Date:  2021-08-10       Impact factor: 17.425

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.